MedTrace Logo

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies

NCT02997813 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2016-12-20

No results posted yet for this study

Summary

This is a retrospective observational cohort database analysis. The study will review retrospectively the records of patients undergoing a first peripheral blood stem cell mobilization for multiple myeloma in the databases from approximately 15 hospitals which are part of the IFM collaborative group. Patient records will be divided into two groups of 50 patients minimum, maximum 100 patients or up to the number of patient records that could be extracted. The first group of patients will have received plerixafor plus G-CSF without the administration of chemotherapy as a mobilization strategy and a second group of patients will have received cyclophosphamide plus G-CSF as a mobilization strategy.

All consecutive patients with complete set of data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and plerixafor and all consecutive patients with complete data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and cyclophosphamide will be included.

All data that will be analyzed will be extracted from the selected IFM institutions which are located in France.

Conditions

Sponsors & Collaborators

  • Intergroupe Francophone du Myelome

    lead NETWORK

Principal Investigators

  • Xavier Leleu, Dr · Service des maladies du sang, Hôpital Huriez, CHRU, Lille

  • Denis Caillot, Dr · Service d'Hématologie Clinique, Hôpital Le Bocage, CHU Dijon

  • Eric Deconinck, Pr · Hématologie, Hôpital Jean Minjoz, CHU Besançon

  • Samuel Limat, Pr · Pharmacie centrale, Hôpital Jean Minjoz, CHU Besançon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-12-31
Completion
2016-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02997813 on ClinicalTrials.gov